Dr. Andrew Irving was formerly a senior lecturer in neuropharmacology at Dundee University and more recently part of the neuroscience team at University College Dublin. Andrew has published extensively in the field of cannabinoids over the past 20 years.  Much of his recent work has involved investigating the properties of the novel cannabinoid receptor, GPR55 and related lipid-sensing receptors, which offer potential as novel therapeutic targets for cannabinoids with more focused activities and reduced adverse effects.